PTO/SB/68 (09-06)
Approved for use through 3/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14	
Bring completed form to: File Information Unit, Room 2EORECEIVED  Application Number  Arlington, VA 22202-3514  NUV 0 3 20868 / 808 C 29  Telephone: (703) 308-2733  Paper No. 427	
Telephone: (703) 308-2733	
File Information Unit  I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):	
United States Patent Application Publication No, pa	
United States Patent Number 200 4 00 23 % 9, column, line, or	
WIPO Pub. No, page, line	-
Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General  A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room.  The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).  For published applications that are still pending, a member of the public may obtain a copy of:  the file contents; the pending application as originally filed; or any document in the file of the pending application.  For unpublished applications that are still pending:  (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application, or an international patent application in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.  (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.	
- Shoais ahougar	11-03-06
Signature	Date
Typed or printed name	FOR PTO USE ONLY
Registration Number, if applicable	Approved by:
703-553- 0080 Telephone Number	Unit: File Information Unit
Total Traines.	

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS BRING TO File Information Unit Process 2504, 2000 Casefal Drive, Adjunctor, Virginia FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.



(19) United States

## (12) Patent Application Publication (10) Pub. No.: US 2004/0023909 A1

Roy-Chowdhury et al.

(43) Pub. Date:

Feb. 5, 2004

(54) PROCESS FOR PREVENTING OR REDUCING UNDESIRABLE IMMUNOLOGICAL EFFECTS TO INFECTIOUS AGENTS IN SUBJECTS

(75) Inventors: Jayanta Roy-Chowdhury, New Rochelle, NY (US); Yaron Ilan, Bronx, NY (US); Elazar Rabbani, New York, NY (US); Dean L. Engelhardt, New York, NY (US)

> Correspondence Address: **HUNTON & WILLIAMS** INTELLECTUAL PROPERTY DEPARTMENT 1900 K STREET, N.W. **SUITE 1200** WASHINGTON, DC 20006-1109 (US)

(73) Assignee: Enzo Therapeutics, Inc

(21) Appl. No.:

10/377,603

(22) Filed:

Mar. 4, 2003

## Related U.S. Application Data

Continuation of application No. 09/447,704, filed on Nov. 23, 1999, now abandoned, which is a division of application No. 08/808,629, filed on Feb. 28, 1997, now abandoned

## **Publication Classification**

(51) Int. Cl.<sup>7</sup> ...... A61K 39/395; A61K 48/00 (52) U.S. Cl. ...... 514/44; 424/93.2; 424/145.1

## **ABSTRACT**

Novel immune modulating processes are provided in which the imunological state of a subject including mature subjects, mammals and humans, are down regulated in a selective manner, and as a subset in a dominant manner. The novel immunological state termed SIDR for selective immune down regulation is usefully applied to the immunological modulation or regulation of gene delivery components, artificially expressed genes, gene delivery systems and expression products of artificially introduced genes by such delivery systems, and infectious agents. SIDR is also useful when combined with other immune modulating treatments such as general immune suppression and anti-apoptosis. SIDR may also be used to selectively down regulate the immune response system of a subject to a wide variety of noncellular immunogenic components and to native antigens. Other processes for producing immune suppression by administering macromolecules or compounds to a subject so as to obtain or effect SIDR are also provided. Kits for carrying out the novel processes are also provided.